Comscore announced a net loss of $65.5 million in Q3 2026, primarily due to a $57.3 million non-cash goodwill impairment and restructuring costs. Revenue declined 14.3% year-over-year to $76.2 million, impacted by the divestiture of its Movies business and lower syndicated digital product sales. Despite these challenges, the company reaffirmed its full-year 2026 revenue guidance of $315 million to $325 million and expects to achieve $20-$25 million in annual cost savings from its realignment plan. Comscore is focused on transforming its business and investing in long-term growth opportunities in 2027.
Comscore's Q3 2026 results provide context for readers interested in media companies. For readers following the Media sector, here is Pluang's market snapshot as of Nov 04, 2026 03:41 WIB: Among 57 priced US media stocks, 30 advanced while 27 declined. Notably, Reddit Inc (RDDT) rose 5.26% to USD 95.77 with a typical hold time of 27 days, Trump Media and Technology Group Corp (DJT) increased 4.95% to USD 5.94 despite 100% sell order activity, and Liberty Global Ltd Class C (LBTYK) gained 4.44% to USD 8.35 with a 22-day hold time.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
